​

RenovoRx Stock (NASDAQ:RNXT)

ForecastRevenueOwnershipFinancialsChartTranscripts
RenovoRx by TradingView

Previous Close

$1.27

52W Range

$0.75 - $1.69

50D Avg

$1.31

200D Avg

$1.16

Market Cap

$45.72M

Avg Vol (3M)

$163.48K

Beta

1.27

Div Yield

-

RNXT Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Aug 26, 2021

Website

RNXT Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24
Other Operating Segment$43.00K

Fiscal year ends in Dec 24 | Currency in USD

RNXT Financial Summary

Dec 24Dec 23Dec 22
Revenue$43.00K--
Operating Income$-10.97M$-11.40M$-9.95M
Net Income$-8.81M$-10.23M$-9.77M
EBITDA$-10.97M$-11.39M$-9.94M
Basic EPS$-0.04$-0.99$-1.08
Diluted EPS$-0.04$-0.99$-1.08

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 15, 25 | 4:30 PM

Peer Comparison

TickerCompany
RNAZTransCode Therapeutics, Inc.
ABVCABVC BioPharma, Inc.
VRPXVirpax Pharmaceuticals, Inc.
KTTAPasithea Therapeutics Corp.
INDPIndaptus Therapeutics, Inc.
FBRXForte Biosciences, Inc.